ABL receives CE-IVD registration for its UltraGene Combo2Screen SARS-CoV-2 assay

▴ abl-receives-ce-ivd-registration-new-diagnostics-tool
A new breakthrough reported by ABL to fight the pandemic SARS-COVID-2

Advanced Biological Laboratories (ABL) announced today the CE-IVD registration of its UltraGene Combo2Screen SARS-CoV-2 assay, now available for in-vitro diagnostics use.

This test is intended to be used for the qualitative detection of nucleic acids from severe acute respiratory syndrome-associated coronavirus 2 (SARS-CoV-2) in a clinical specimen. The real-time RT-PCR test aids the diagnosis of coronavirus disease (Covid-19) infection.

Targeting the N gene + E gene regions of the SARS-CoV-2 genome (in full compliance with the WHO Guidelines) in a multiplex format with internal control for the reverse transcription and PCR steps, the UltraGene Combo2Screen CE-IVD assay is a fast and easy-to-use diagnostic solution with the highest TCID50 sensitivity (1*10-6 TCID50/mL). The specimen is intended to be collected from nasopharyngeal swab. It is compatible with most automatic or manual RNA extraction methods, as well as with most qPCR instruments equipped with at least three channels.

The test developed by Advanced Biological Laboratories, will complement a large menu of molecular biology assays dedicated to the management of infectious diseases, including DeepChek-8-plex CoV-2 Genotyping Assay; a target-specific PCR kit with downstream next generation sequencing (NGS) analysis software. This application is for Research Use Only (RUO). It shall help in the research field (genotyping, surveillance studies) about the SARS-CoV-2 virus

“Receiving the CE-IVD mark for our UltraGene Combo2Screen assay is a major milestone for ABL. It will help additional virology labs perform SARS CoV-2 detection and improve the overall management of patients suffering from COVID-19 disease worldwide,” said Dimitri Gonzalez, Head of the Diagnostics division of ABL. “Our company is committed to delivering the highest quality products.”

“The ABL regulatory team has been rigorous in the verification and validation of our molecular diagnostics application, including the QCMD external quality assessment panel and the external performance validation by the french Covid-19 national reference centre (CNR Lyon)” added Mr. Ronan Boulmé, Governance, Risk and Compliance Manager of the ABL Group. “This diligence increases the quality of our product solutions overall.”

Tags : #ABL #CE-IVD #RT-PCR #CoronavirusDetection

About the Author


Team Medicircle

Related Stories

Loading Please wait...
-Advertisements-


Trending Now

Pain – a small word but can really make you uncomfortable September 19, 2020
India's coronavirus cases rise to 5.2 million with 96,424 new infections and 87,472 recoveriesSeptember 19, 2020
UV light can kill Covid with our harming human : American Journal of Infection controlSeptember 19, 2020
Israel imposes second coronavirus lockdown during high holidaysSeptember 19, 2020
British DnaNudge coronavirus test is accurate : UK MHRASeptember 19, 2020
Uttar Pradesh conducts 1,50,000 tests per day while NCL donates 50 ambulances September 19, 2020
Male pattern baldness or Alopecia : What you should know September 18, 2020
Huntington Study Group partners with Prilenia Therapeutics : Phase 3 Clinical Study of Pridopidine September 18, 2020
Alarming rates of transmission of virus in EuropeSeptember 18, 2020
China Biopharma plant leak infects thousands with bacterial diseaseSeptember 18, 2020
WHO urges safety for health workers bearing brunt of CoronavirusSeptember 18, 2020
Moderna to seek COVID vaccine's limited emergency useSeptember 18, 2020
Gujarat reports record 1379 new cases of COVID-19 in last 24 hoursSeptember 18, 2020
Global Coronavirus cases surpass 30 MillionSeptember 18, 2020
Karnataka reports 9366 new COVID-19 positive cases in last 24 hoursSeptember 18, 2020
Pulmonary Arterial Hypertension treatment : Moderna and Chiesi Group collaboratesSeptember 18, 2020
Sero survey begins in Chhattisgarh amid rising COVID-19 casesSeptember 18, 2020
WHO calls for protective equipments for frontline medical workersSeptember 18, 2020
Around 15 thousand Railway employees affected by Corona virusSeptember 18, 2020
Elicio Therapeutics collaborates with Moffitt Cancer CenterSeptember 18, 2020